The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Catch up here with the final episode of Adrian's Election Adventure.
Tributes have been paid to Welsh rugby league player Danny Jones, who died while playing for the Keighley Cougars yesterday afternoon.
People in Wales do not undertake the monthly recommended checks for skin cancer, a survey has shown.